First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma—An Update on Patient Selection and Response Evaluation
Author:
Publisher
MDPI AG
Subject
Clinical Biochemistry
Link
http://www.mdpi.com/2075-4418/6/4/44/pdf
Reference41 articles.
1. Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification
2. Sorafenib in Advanced Hepatocellular Carcinoma
3. Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses
4. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
5. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Hypoxia-inducible factor-2α and its missense mutations: potential role in HCC diagnosis, progression, and prognosis and underlying mechanism;Oncology and Translational Medicine;2022-12
2. AZD4547 and the Alleviation of Hepatoma Cell Sorafenib Resistance via the Promotion of Autophagy;Anti-Cancer Agents in Medicinal Chemistry;2022-09-14
3. Sequential Systemic Treatment in Advanced Hepatocellular Carcinoma Is Able to Prolong Median Survival to More than 3 Years in a Selected Real-World Cohort;Visceral Medicine;2020-05-07
4. New systemic agents for hepatocellular carcinoma;Current Opinion in Gastroenterology;2020-05
5. TPGS-1000 exhibits potent anticancer activity for hepatocellular carcinoma in vitro and in vivo;Aging;2020-01-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3